Published in Schizophr Res on May 01, 2003
North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull (2007) 3.28
Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ (2013) 3.06
Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull (2009) 2.90
Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation? Biol Psychiatry (2011) 1.52
Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev (2011) 1.49
Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci (2007) 1.28
The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res (2010) 1.14
Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res (2013) 1.06
Does abnormal sleep impair memory consolidation in schizophrenia? Front Hum Neurosci (2009) 1.02
A randomized trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. J Consult Clin Psychol (2013) 0.98
Comorbidity of physical and mental disorders in the neurodevelopmental genomics cohort study. Pediatrics (2015) 0.95
Recent approaches to psychological interventions for people at risk of psychosis. Eur Arch Psychiatry Clin Neurosci (2006) 0.91
Sleep spindle deficits in antipsychotic-naïve early course schizophrenia and in non-psychotic first-degree relatives. Front Hum Neurosci (2014) 0.90
Evaluating and treating the prodromal stage of schizophrenia. Curr Psychiatry Rep (2004) 0.88
Predicting the risk of psychosis onset: advances and prospects. Early Interv Psychiatry (2012) 0.87
Maladaptive schemas as a mediator between social defeat and positive symptoms in young people at clinical high risk for psychosis. Early Interv Psychiatry (2011) 0.87
Neonatal behavioral changes in rats with gestational exposure to lipopolysaccharide: a prenatal infection model for developmental neuropsychiatric disorders. Schizophr Bull (2010) 0.85
Reduced Sleep Spindles in Schizophrenia: A Treatable Endophenotype That Links Risk Genes to Impaired Cognition? Biol Psychiatry (2015) 0.83
Emotion recognition deficits as predictors of transition in individuals at clinical high risk for schizophrenia: a neurodevelopmental perspective. Psychol Med (2015) 0.82
Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. Early Interv Psychiatry (2014) 0.82
Is pharmacological intervention necessary in prodromal schizophrenia? Shanghai Arch Psychiatry (2012) 0.79
Treating early psychosis: who, what, and when? Dialogues Clin Neurosci (2005) 0.79
Sleep in patients with schizophrenia. Curr Sleep Med Rep (2015) 0.78
The 'at-risk mental state' for psychosis in adolescents: clinical presentation, transition and remission. Child Psychiatry Hum Dev (2014) 0.78
Assessing depression in youth at clinical high risk for psychosis: a comparison of three measures. Psychiatry Res (2013) 0.77
Cognitive behavioral therapy in prodromal psychosis. Curr Pharm Des (2012) 0.75
A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol (1994) 5.47
One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry (1994) 5.29
The Collaborative Longitudinal Personality Disorders Study: reliability of axis I and II diagnoses. J Pers Disord (2000) 4.99
Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry (2008) 4.14
WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res (2000) 4.07
A depression rating scale for schizophrenics. Schizophr Res (1991) 3.70
Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA (2000) 3.52
Multicenter collaborative panic disorder severity scale. Am J Psychiatry (1997) 3.29
Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl (1993) 3.24
Symptom assessment in schizophrenic prodromal states. Psychiatr Q (1999) 3.09
Treatment utilization by patients with personality disorders. Am J Psychiatry (2001) 3.03
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol (1993) 2.92
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer (1992) 2.91
Cognitive effects of corticosteroids. Am J Psychiatry (1990) 2.85
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry (2000) 2.66
The Collaborative Longitudinal Personality Disorders Study: development, aims, design, and sample characteristics. J Pers Disord (2000) 2.58
An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Ann Intern Med (1999) 2.56
Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res (1992) 2.49
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993. Psychiatr Serv (2000) 2.43
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry (2000) 2.34
Structure of 3' terminal region of type II human T lymphotropic virus: evidence for new coding region. Science (1984) 2.32
Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull (2008) 2.32
A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr (1979) 2.32
Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. Alcohol Clin Exp Res (1992) 2.25
Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (1997) 2.20
The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry (1987) 2.19
Childhood abuse in first-episode psychosis. Br J Psychiatry (1994) 2.17
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry (1999) 2.15
Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst (2001) 2.09
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry (2012) 2.07
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet (1997) 2.02
Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psychiatry (1998) 2.00
Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res (2000) 1.98
Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex. Psychophysiology (1991) 1.95
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry (2001) 1.94
5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry (1998) 1.94
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry (2000) 1.93
Embryonic-fetal erythroid characteristics of a human leukemic cell line. Proc Natl Acad Sci U S A (1980) 1.90
Duration of untreated psychosis: impact on 2-year outcome. Psychol Med (2004) 1.88
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 1.88
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol (2001) 1.86
Role of members of the Wnt gene family in human hematopoiesis. Blood (1998) 1.86
Extent of comorbidity between mental state and personality disorders. J Pers Disord (1997) 1.81
The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. Am J Psychiatry (1987) 1.80
Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest (1977) 1.79
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol (2001) 1.79
Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA (1990) 1.78
Synaptic elimination, neurodevelopment, and the mechanism of hallucinated "voices" in schizophrenia. Am J Psychiatry (1997) 1.76
Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi. Blood (2001) 1.74
The treatment of lead poisoning from gunshot wounds with succimer (DMSA) J Toxicol Clin Toxicol (1994) 1.72
Early detection strategies for untreated first-episode psychosis. Schizophr Res (2001) 1.72
Patterns of premorbid functioning in first episode psychosis: relationship to 2-year outcome. Acta Psychiatr Scand (2005) 1.71
Parallel distributed processing and the emergence of schizophrenic symptoms. Schizophr Bull (1993) 1.70
Facial affect recognition and information processing in schizophrenia and bipolar disorder. Schizophr Res (1998) 1.70
Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. J Pediatr (1996) 1.69
The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities. Arch Gen Psychiatry (1986) 1.68
Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry (1992) 1.66
Early intervention in psychosis: keeping faith with evidence-based health care. Psychol Med (2009) 1.64
Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry (1998) 1.64
Effects of fixed-ratio sample and choice response requirements upon oddity matching. J Exp Anal Behav (1977) 1.63
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry (1999) 1.63
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol (1988) 1.62
Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand (2002) 1.60
The relationship between panic disorder and major depression. A new family study. Arch Gen Psychiatry (1993) 1.59
Unipolar mania reconsidered: evidence from an elderly cohort. Br J Psychiatry (1994) 1.57
Effects of response-produced stimuli upon conditional discrimination performance. J Exp Anal Behav (1974) 1.57
Treatment of schizophrenia. Lancet (1995) 1.56
Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry (1993) 1.55
Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab (1997) 1.55
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J Clin Psychiatry (2000) 1.54
Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis (1994) 1.54
Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Arch Gen Psychiatry (1988) 1.53
Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull (2001) 1.53
Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant (2006) 1.52
Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychol Med (1998) 1.52
Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand (2011) 1.52
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry (1998) 1.51
Baseline and fear-potentiated startle in panic disorder patients. Biol Psychiatry (1994) 1.49
The influence of disclosure of HIV diagnosis on time to disease progression in a cohort of Romanian children and teens. AIDS Care (2007) 1.49
Neurocognitive and social functioning in schizophrenia. Schizophr Bull (1999) 1.49
Neurodynamics and schizophrenia research: editors' introduction. Schizophr Bull (1993) 1.48
Borderline personality disorder in adolescents: ubiquitous or specific? Am J Psychiatry (1994) 1.48
Gender and affect in schizophrenia. Can J Psychiatry (1996) 1.47
Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch Gen Psychiatry (1989) 1.47
Factorial structure of the Scale of Prodromal Symptoms. Schizophr Res (2004) 1.47
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res (2003) 1.47